1. According to statistics, 65%-85% of hyperandrogenemia patients are patients with polycystic ovary syndrome (PCOS). Hyperandrogenemia plays an important role in the pathogenesis of PCOS. On the one hand, the high androgen concentration in the ovary inhibits follicular maturation and prevents the development of dominant follicles, which leads to multiple atretic follicles and polycystic ovarian changes (PCOS). This in turn promotes the secretion of androgens by the ovaries and adrenal glands, thus creating a vicious cycle of excess androgens and persistent anovulation. In PCOS patients, the ovaries are enlarged and the number of small follicles increases abnormally, which increases the sensitivity of the ovaries to endogenous and exogenous gonadotropins, which directly stimulate follicle production in concert with FSH and increase follicle recruitment; the pituitary gland secretes low FSH relative to LH, which is insufficient to reach the threshold of follicle recruitment to selection and thus cannot produce dominant follicles. Therefore, the only effective way to treat this disease is to change the endocrine function of the ovaries and promote ovulation. 2.Characteristics of Diane-35 Daying I-35 is a compound preparation containing 2mg of cyproterone acetate and 0.035mg of ethinyl estradiol, which can reduce androgens, decrease the accumulation of fat in peripheral tissues, make the body mass index decrease significantly, reduce peripheral fat aromatase, stop the vicious cycle of peripheral hormones, and enhance the ovulation-promoting effect. It also prevents the occurrence of a series of metabolic diseases such as hypertriglyceridemia and very low-density lipoprotein cholesterolemia due to obesity. It can prevent the entry of androgen receptor complex into the nucleus by competing with androgens for receptors in target organs; inhibit the synthesis of cytochrome P4-dependent steroids, as well as inhibit androgens of ovarian and adrenal origin; and have anti-androgenic effects and inhibit the release of pituitary LH and FSH. The results of this paper show that the application of Diane I 35 treatment, its effective control of high LH and hyperandrogenemia, normalize endocrine parameters, significantly improve the clinical symptoms and signs of patients, and improve the success rate of ovulation treatment, this study first Diane I 35 3 cycles, so that patients LH, T levels significantly decreased, and greatly improve the pregnancy rate. The incidence of miscarriage could be reduced because of the strong progestogenic effect of Diane I-35.